Abstract
Despite tremendous research efforts focused on diagnosis and treatment, pancreatic ductal adenocarcinoma remains the third leading cause of cancer-related death in the United States, with a 5-year overall survival rate of less than 5%. Although resistance is rather complex, emerging evidence has demonstrated that epigenetic alterations (e.g. miRNA) have important roles in PDAC progression as well as resistance to therapy. Certain miRNAs have been identified as potential prognostic biomarkers in PDAC. In this review, we summarize the recent developments in miRNA research related to PDAC therapeutic resistance mechanisms and the potential of miRNAs as prognostic biomarkers for future clinical management of PDAC.
| Original language | English |
|---|---|
| Article number | 18 |
| Journal | Biomarker Research |
| Volume | 6 |
| Issue number | 1 |
| DOIs | |
| State | Published - May 21 2018 |
Keywords
- Biomarkers
- Chemotherapy
- Gemcitabine
- MiRNA
- Pancreatic ductal adenocarcinoma
- Prognosis
- Resistance
Fingerprint
Dive into the research topics of 'microRNA based prognostic biomarkers in pancreatic Cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver